Resumen del estudio

Two hundred forty patients with chronic midportion Achilles tendinopathy were randomized to receive either a single platelet-rich plasma (PRP) injection (n=121) or a sham subcutaneous dry needle injection (n=119). The primary outcome was the VISA-A score at 6 months, which assesses pain, function, and activity limitations related to Achilles tendinopathy. Secondary outcomes included the VISA-A score at 3 months, pain via visual analog scale (VAS), and health-related quality of life using EQ-5D-5L at multiple follow-up points (2 weeks, 3 months, and 6 months). Overall, the results of the study revealed no significant difference between the PRP and sham groups in any of the measured outcomes, including the primary VISA-A score at 6 months. These findings suggest that a single PRP injection does not provide clinical benefit over a sham injection for chronic midportion Achilles tendinopathy.